The CEPI Preclinical Model Network is refining transgenic hDPP4 mouse and hamster models, as well as NHP models, and partnering with vaccine developers for product testing in appropriate models.
Several preclinical studies have used BALB/c or C57BL/6 mice, with and without MERS-adapted strains, to study the cellular and humoral immune responses to MERS and MERS vaccine candidates.
- Abiona 2025: MERS-CoV spike vaccine-induced N-terminal domain-specific antibodies are more protective than receptor binding domain-specific antibodies
- Sims 2025: Dysregulation of lung epithelial cell homeostasis and immunity contributes to Middle East respiratory syndrome coronavirus disease severity
- Chao 2024: Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
- Shen 2024: DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice
- Hutchinson 2023: Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera
- Tai 2023: MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection